Revance Therapeutics (NASDAQ:RVNC) Research Coverage Started at StockNews.com

by · The Cerbat Gem

StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Free Report) in a research report report published on Monday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Nine analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, Revance Therapeutics currently has an average rating of “Hold” and an average target price of $8.39.

View Our Latest Research Report on Revance Therapeutics

Revance Therapeutics Stock Performance

Shares of RVNC stock opened at $3.65 on Monday. The firm’s 50 day moving average price is $3.65 and its 200-day moving average price is $3.77. Revance Therapeutics has a one year low of $2.30 and a one year high of $6.65. The firm has a market cap of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90.

Hedge Funds Weigh In On Revance Therapeutics

Several large investors have recently bought and sold shares of the stock. Natixis acquired a new stake in shares of Revance Therapeutics in the 4th quarter valued at about $31,000. Two Sigma Securities LLC acquired a new stake in shares of Revance Therapeutics in the fourth quarter valued at approximately $35,000. Alpine Global Management LLC purchased a new position in shares of Revance Therapeutics during the fourth quarter worth approximately $37,000. RPO LLC acquired a new position in shares of Revance Therapeutics in the 4th quarter valued at $55,000. Finally, Fairfax Financial Holdings Ltd. Can acquired a new position in shares of Revance Therapeutics in the 4th quarter valued at $64,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Revance Therapeutics

(Get Free Report)

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

See Also